Brief: Insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies
BRIEF-Insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies Oct 15 (Reuters) - AstraZeneca PLC AZN.L:
INSITRO ANNOUNCES A STRATEGIC COLLABORATION WITH ASTRAZENECA FOR AI-ENABLED DISCOVERY OF NOVEL THERAPEUTICS FOR MASH AND CARDIOMYOPATHIES
INSITRO: UNDER TERMS, CO TO RECEIVE $40 MILLION UPFRONT, ELIGIBLE FOR UP TO ABOUT $1.46 BILLION IN POTENTIAL DISCOVERY, DEVELOPMENT, & COMMERCIAL MILESTONES
Source text: ID:nBwb83FNDa
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca fends off lawsuit over alleged Soliris drug monopoly (updated)
AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
Sofinnova closes €725 million fund to back European biotech expansion
AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
UK Stocks-Factors to watch on November 16 (updated)